| Title |
Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure
|
|---|---|
| Published in |
Drug Design, Development and Therapy, February 2017
|
| DOI | 10.2147/dddt.s130945 |
| Pubmed ID | |
| Authors |
Fazia Mir, Alp S Kahveci, Jamal A Ibdah, Veysel Tahan |
| Abstract |
Hepatitis C virus (HCV) is a global pandemic, with nearly 200 million infected patients worldwide. HCV is the most common blood-borne infection in the US with numerous health implications including liver fibrosis, cirrhosis, and hepatocellular cancer. Traditional genotype-based HCV therapies with interferon resulted in moderate success in the sustained elimination of viral genome. Recent clinical trials of the once-daily combination tablet of sofosbuvir, a nonstructural (NS) 5B polymerase inhibitor, and velpatasvir, an NS5A inhibitor, demonstrate sustained virologic response rates of about 95%, regardless of prior treatment experience or presence of cirrhosis across all HCV genotypes. Patients reported improvements in general health, fatigue, and emotional and mental well-being after completing combination therapy. The combination treatment is effective, but does need to be administered with caution in patients receiving certain medications or with certain diseases. Herein, we review the safety and efficacy of sofosbuvir/velpatasvir combination regimen for all HCV genotypes. |
Mendeley readers
The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 49 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 8 | 16% |
| Student > Bachelor | 8 | 16% |
| Student > Ph. D. Student | 5 | 10% |
| Student > Master | 5 | 10% |
| Student > Doctoral Student | 4 | 8% |
| Other | 10 | 20% |
| Unknown | 9 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 49% |
| Biochemistry, Genetics and Molecular Biology | 4 | 8% |
| Nursing and Health Professions | 3 | 6% |
| Immunology and Microbiology | 3 | 6% |
| Agricultural and Biological Sciences | 2 | 4% |
| Other | 4 | 8% |
| Unknown | 9 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 April 2022.
All research outputs
#6,476,524
of 25,382,440 outputs
Outputs from Drug Design, Development and Therapy
#420
of 2,268 outputs
Outputs of similar age
#111,831
of 424,972 outputs
Outputs of similar age from Drug Design, Development and Therapy
#13
of 45 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 424,972 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 45 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.